Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multiple dose pharmacokinetic (PK) comparison of ralinepag extended-release (XR) and ralinepag/selexipag immediate-release (IR) formulations in healthy subjects

Next Previous
Trial Profile

A multiple dose pharmacokinetic (PK) comparison of ralinepag extended-release (XR) and ralinepag/selexipag immediate-release (IR) formulations in healthy subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 May 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ralinepag (Primary) ; Ralinepag; Selexipag
  • Indications Pulmonary arterial hypertension
  • Focus Pharmacokinetics

Most Recent Events

  • 07 May 2019 New trial record
  • 06 Apr 2019 Results assessing pharmacokinetics of extended release tablet formulation of ralinepag over both ralinepag and selexipag IR formulations in healthy subjects, presented at the 39th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top